# Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration

> **NCT05008341** · PHASE1 · COMPLETED · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Narcolepsy
- Obstructive Sleep Apnea
- Excessive Daytime Somnolence
- Excessive Sleepiness
- Postpartum

## Interventions

- **DRUG:** Solriamfetol 150 mg Oral Tablet

## Key facts

- **NCT ID:** NCT05008341
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-27
- **Primary completion:** 2022-04-15
- **Final completion:** 2022-04-15
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05008341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05008341, "Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05008341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*